BlueCross BlueShield
Federal Employee Program

XALKORI
(crizotinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Recurrent or metastatic non-small cell lung cancer (NSCLC)
    a. 18 years of age or older
    b. Patient must have **ONE** of the following:
        i. Tumor is positive for ALK mutation as determined by an FDA-approved test
        ii. Tumor is positive for ROS-1 mutation, as determined by an FDA-approved test
        iii. Tumor has MET amplification or MET exon 14 skipping mutation

2. Inflammatory myofibroblastic tumor (IMT)
    a. 18 years of age or older
    b. Tumor is positive for ALK mutation

3. Unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)
    a. 1 year of age or older
    b. Tumor is positive for ALK mutation

4. Relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL)
    a. 1 to 21 years of age
    b. Tumor is positive for ALK mutation

AND ALL of the following for **ALL** indications:

1. Ophthalmology examination at baseline and periodically throughout treatment

2. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Xalkori and for at least 45 days after the last dose
3. Males with female partners of reproductive potential **only**: patient will be advised to use condoms during treatment with Xalkori and for at least 90 days after the last dose

Prior - Approval Limits

Quantity 360 capsules per 90 days **OR**
720 oral pellets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Recurrent or metastatic non-small cell lung cancer (NSCLC)
    a. 18 years of age or older
2. Inflammatory myofibroblastic tumor (IMT)
    a. 18 years of age or older
3. Unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)
    a. 1 year of age or older
4. Relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL)
    a. 1 to 21 years of age

AND ALL of the following for **ALL** indications:

1. **NO** symptoms indicative of treatment-related pneumonitis
2. Ophthalmology examinations are done periodically throughout treatment
3. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Xalkori and for at least 45 days following the last dose

4. Males with female partners of reproductive potential **only**: patient will be advised to use condoms during treatment with Xalkori and for at least 90 days after the last dose

Prior – Approval *Renewal* Limits

Same as above